Endometriosis affects ~176 million women worldwide, yet on average, women experience pain 27 ~10 years from symptom onset before being properly diagnosed. Standard treatments (drugs or 28 surgery) often fail to provide long-term pain relief. Elevated levels of reactive aldehydes such as 29 4-hydroxynonenal (4-HNE) have been implicated in the peritoneal fluid of women with 30 endometriosis and upon accumulation, reactive aldehydes can form protein-adducts and/or 31 generate pain. A key enzyme in detoxifying reactive aldehydes to less reactive forms, is the 32 mitochondrial enzyme aldehyde dehydrogenase-2 (ALDH2). Here, we tested the hypothesis that 33 aberrant reactive aldehyde detoxification by ALDH2, underlies endometriosis and its associated 34 pain. We determined, in the eutopic and ectopic endometrium of women with severe (stage IV) 35 peritoneal endometriosis, that ALDH2 enzyme activity was decreased, which was associated with 36 decreased ALDH2 expression and increased 4-HNE adduct formation compared to the eutopic 37 endometrium of controls in the proliferative phase. Using a rodent model of endometriosis and 38 an ALDH2*2 knock-in mouse with decreased ALDH2 activity, we determined that increasing 39 ALDH2 activity with the enzyme activator Alda-1 could prevent endometriosis lesion 40 development as well as alleviate pain-associated behaviors in proestrus. Overall, our findings 41 suggest that targeting the ALDH2 enzyme in endometriosis may lead to better treatment strategies 42 and in the proliferative phase, that increased 4-HNE adduct formation within the endometrium 43 may serve as a less invasive diagnostic biomarker to reduce years of suffering in women. 44 45 46 47 48 49 50 51 52 53 54 Endometriosis is an estrogen dependent inflammatory condition defined by the growth of 55 endometrial tissue in extrauterine locations (variously called lesions, cysts, ectopic growths, 56 implants). The condition affects ~176 million women worldwide, yet little progress has been made 57 over the past 20 years relative to screening, detection, prognosis, and treatment (1). The most 58 common symptom of endometriosis is pain and 70-90% of women of reproductive age with 59 chronic pelvic pain (CPP), have endometriosis (2). Painful symptoms include debilitating 60 pelvic/abdominal pain, dyspareunia (vaginal hyperalgesia, pain during intercourse), severe 61 dysmenorrhea (pain on menstruation), dyschezia (pain on defecation), and dysuria (pain with 62 urination). Women with the condition also suffer from co-occurring painful conditions including 63 interstitial cystitis/painful bladder syndrome, irritable bowel syndrome, vulvodynia, fibromyalgia, 64 and up to 50% of these women also suffer from infertility (3, 4). A major clinical problem is that 65 painful symptoms associated with endometriosis poorly correlate with disease extent and on 66 average, women experience pain ~10 years before being properly diagnosed (5-7). The gold 67 standard for endometriosis diagnosis is laparoscopic visualization of the lesions preferably with 68 histological confirmation, which is invasive and expensive. Available treatments for 69 endometriosis include drugs and/or surgery, which tend to be ineffective over the long-term and 70 can produce unwanted side effects premature bone loss, vaginal dryness, and contraception. Thus, 71 there is a need for more effective pain therapeutics and less invasive diagnostic strategies to reduce 72 years of suffering in women with endometriosis. 73 How endometriosis occurs is not fully understood and is considered an enigma. The leading 74 hypothesis, Sampson's hypothesis, suggests retrograde menstruation underlies the disease, in 75 which the endometrial lining (endometrium) of the uterus travels retrogradely through the fallopian 76 tubes and implants, primarily in the peritoneal cavity (8). However, ~90% of women experience 77 retrograde menstruation but only ~10% have endometriosis, suggesting differences within the 78 endometrium, possibly genetic, underlie the ability of the ectopic lesion to successfully implant, 79
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To determine if decreased ALDH2 enzyme activity contributes to endometriosis pain-associated 144 behaviors, behavioral assessments were made in proestrus in wild type and ALDH2*2 mice for 2 145 weeks before endometriosis was induced and then during the 2 week time period that 146 endometriosis becomes established (Fig. 4A) . At baseline, no significant differences were 147 observed between wild type and ALDH2*2 mice relative to abdominal directed licking (events in 148 5 min period), paw withdrawal threshold, or thermal latency ( Fig. 4B-D) . 149 compared to baseline, both wild type and ALDH2*2 mice had increased (P < 0.0005 and P < 150 0.0001) abdominal directed licking, decreased (P < 0.0001 and P < 0.0001) paw withdrawal 151 thresholds, and decreased (P < 0.0001 and P < 0.0001) thermal latencies, relative to their respective 152 baselines. Post-endometriosis, ALDH2*2 mice compared to wild type mice, had increased (P < 153 0.05) abdominal licking suggesting that the decreased ALDH2 activity exacerbated local 154 abdominal discomfort (Fig. 4B ). To assess for differences in locomotor activity, an automated 155 Opto-Varimex activity monitor recorded the total, ambulatory, and vertical counts in a 5 min 156 period ( Fig. 4E and fig. S1A and B ). No significant differences in locomotor activity were 157 observed between wild type and ALDH2*2 mice at baseline, or within groups post-endometriosis 158 relative to baseline, or between groups post-endometriosis. To assess for differences in 159 exploratory behavior, a modified home cage open field setting with a cardboard tunnel was used. 160 The total time spent in the tunnel (s), number of tunnel entries, and the number of times the mouse 161 climbed on top of the tunnel was recorded in a 5 min period ( Fig. 4F and fig. S1C and D). At 162 baseline, no significant differences were observed between wild type and ALDH2*2 mice relative 163 to total time in tunnel (s) or number of times on top of the tunnel, but ALDH2*2 mice had a 164 decreased (P < 0.05) number of tunnel entries, relative to wild type mice ( fig. S1C ). Post-165 endometriosis, in ALDH2*2 mice, total time in tunnel (s), compared to baseline, was significantly 166 decreased (P < 0.005; Fig. 4F ). No other significant differences were found between or within 167 groups relative to exploratory behavior. Overall, these findings suggest that the decreased ALDH2 168 activity of the ALDH2*2 mouse exacerbates endometriosis abdominal pain-associated behavior. To determine if increasing ALDH2 enzyme activity could prevent lesion development, we 172 incorporated with our rodent endometriosis model, the small molecule Alda-1[N-(1,3-benzodioxo-173 5-ylmethyl)-2,6-dichlorbenzamide] that selectively increases ALDH2 activity by correction of the 174 ALDH2*2 mutant structural deficit (20) . Beginning the day of endometriosis surgery, in wild type 175 and ALDH2*2 mice, Alzet osmotic pumps were implanted for continuous delivery of Alda-1 176 (5mg/kg) or DMSO PEG50/50% (control). Mice were then sacrificed, lesions measured, and 177 average area determined for both wild type and ALDH2*2 mice at one of two developmental time 178 points: day 3 or 28 ( Fig. 5A ). By day 3, ALDH2*2 mice treated with Alda-1 had smaller (P < 179 0.0005) lesion areas compared to DMSO treated ALDH2*2 mice ( Fig. 5B ). By day 28, both wild 180 type and ALDH2*2 mice treated with Alda-1 had smaller (P < 0.005 and P < 0.05, respectively) 181 lesion areas compared to respective DSMO treated groups (Fig. 5C ). Comparing wild type and 182 ALDH2*2 mice, treated with DMSO, at day 3, ALDH2*2 mice lesion area was larger (P < 0.05) 183 than that of wild type mice ( Fig. 6A ) but by day 28, no significant differences were found between 184 DMSO treated wild type and ALDH2*2 mice relative to lesion areas. Comparing wild type and 185 ALDH2*2 mice, treated with Alda-1, no significant differences in lesion area were found at day 3 186 or day 28 ( Fig. 5C and D) . Overall, these findings suggest that Alda-1 prevents the accelerated 187 lesion development seen at day 3 in ALDH2*2 mice, relative to wild type mice (Fig. 3C ), and that 188 by day 28, Alda-1 prevents lesion development in both wild type and ALDH2*2 mice, supporting 189 the involvement of ALDH2 activity in endometriosis development. 192 To determine if increasing ALDH2 enzyme activity could alleviate pain-associated behaviors once 193 endometriosis is established, Alda-1 (or DMSO PEG50/50% control) treatment was delivered via 194 Alzet osmotic pump beginning 2 weeks post-endometriosis and continued for 2 weeks (Fig. 6A ).
Increasing ALDH2 activity alleviates endometriosis pain-associated behaviors in a rodent model

195
Behavioral assessments were made before and after endometriosis was induced and then again S2C and D). Further, no significant differences in locomotor activity were found between Alda-1 227 treated wild type and ALDH2*2 endometriosis mice, compared to their respective DMSO groups.
228
Overall, these findings suggest that increasing ALDH2 activity with Alda-1, can alleviate 229 endometriosis pain-associated behaviors in both wild type and ALDH2*2 mice without 230 influencing locomotor activity but in ALDH2*2 mice, exploratory behavior may be influenced.
231
To determine if Alda-1's alleviation of endometriosis pain-associated behaviors was associated 232 with lesion parameters, the average area, number of lesions, and total lesion burden was analyzed 233 9 and compared post-treatment. In wild type and ALDH2*2 mice treated with Alda-1, no significant 234 differences were found in average lesion area, relative to respective DMSO treated mice ( fig. S2E ).
235
However, in both Alda-1 treated wild type and ALDH2*2 mice, the number of lesions were 236 decreased (P < 0.0001 and P < 0.0001, respectively) compared to respective DMSO treated mice 237 ( Fig. 6G ). To account for the reduced lesion number, the total lesion burden or total amount of 238 ectopic growth for each group was analyzed and compared. In Alda-1 treated wild type mice, total 239 lesion burden was significantly decreased (P < 0.0001) relative to that of DMSO treated mice; Using a rodent model of endometriosis and an ALDH2*2 knock-in mouse, with reduced ALDH2 257 activity and expression and similar basal levels of 4-HNE adducts, relative to wild type mice, we 258 provide evidence that early in endometriosis development, decreased ALDH2 activity accelerates 259 lesion development and exacerbates pain-associated behavior. We further determined that 260 increasing ALDH2 activity with the enzyme activator, Alda-1, could prevent early lesion 261 development. Once endometriosis was established, we determined that increasing ALDH2 activity 262 with Alda-1 treatment, could alleviate endometriosis pain-associated behavior which was 263 associated with a decreased lesion number in both wild type and ALDH2*2 mice and a decreased 264 lesion burden number in wild type mice. Combined, our findings from women with endometriosis 265 and a preclinical rodent model of endometriosis, support our overall hypothesis that aberrant 266 reactive aldehyde detoxification by ALDH2, underlies endometriosis and its associated pain.
267
Overall, our findings suggest that targeting ALDH2 enzyme activity may be effective for the Our findings further suggest that ALDH2 activity influences lesion development and maintenance 295 which has implications for surgery-based treatment strategies for endometriosis-associated pain.
296
In mice, decreased ALDH2 activity exacerbated lesion development whereas increasing ALDH2 for differences within the menstrual cycle; however, we did not control for potential gene 329 expression differences within the days of the proliferative phase (36). In a larger future study, we 330 will analyze additional endometriosis subtypes and days within the proliferative phase. Our 331 analysis will also include biopsies from additional races, particularly East Asians of which ~50% 332 have the ALDH2*2 genetic variant with reduced ALDH2 activity that our ALDH2*2 knock in 333 mouse mimics. Our findings in ALDH2*2 mice may be translatable to women with the ALDH2*2 334 variant; however, a direct link between the E487K mutation and endometriosis must be established 335 in future studies. Further, cell specific ALDH2 characterization in endometrial tissue will 336 performed, as this is yet to be explored.
337
Animal study limitations include the inability to distinguish between the contribution of reduced 37) . Future studies will further test our hypothesis and assess the relationship between ALDH2, 346 4-HNE, and Alda-1 in women and mice with endometriosis.
347
Overall, our findings establish the ALDH2 enzyme as a novel target for endometriosis and its 348 associated pain and Alda-1, as a potentially therapeutic. Further, we provide preliminary support 349 for the development of increased 4-HNE protein adduct formation, in the endometrium, as a 350 biomarker to reduce diagnostic delay and years of suffering in women with endometriosis. weeks. Mutant mice were homozygous ALDH2*2 (ALDH2*2/*2) knock-in mice on a C57BL/6 390 background generated by replacing the mouse wild type ALDH2 allele with a mouse E487K 391 mutant ALDH2 allele by homologous recombination (Fig. 2) . Compared to wild type mice, the 392 ALDH2*2 knock-in mouse has a single amino acid substitution in which adenine is substituted for 393 guanine at the first base pair of codon 487. As a result, there is an amino acid change from 394 glutamic acid (Glu, E) to lysine (Lys, K) that is equivalent to the E487K substitution in the 395 ALDH2*2 human variant, in which ALDH2 enzyme activity is significantly decreased compared 396 to that of wild type mice (41). Founder mice were back-crossed to the C57BL/6 background for 397 at least 7 generations to achieve a homogeneous genetic background as previously described (41).
398
All mice were group housed in a temperature-controlled room (22°C), in Innovive cages lined with 399 chip bedding and ad libitum access to rodent chow and water. Housing was in environmentally 400 controlled conditions (room temperature ~22°C; 12-h light/dark cycle, with lights on at 07:00). Vernon and Wilson and slightly modified by Cummings and Metcalf (43, 44) . Briefly, mice were 411 anesthetized with isoflurane (1-3%) and placed on a heating pad to maintain body temperature 412 (37C). An off-midline (left side) incision was made through the skin and muscle layer to expose 413 the pelvic and abdominal organs. A ~1-cm segment of mid-left uterine horn with its attached fat 414 was ligated proximally and distally with suture. Then, the uterine horn was excised, and the 415 associated fat removed. Three, 2 mm x 2 mm pieces of the excised uterus (minus the fat) were 416 15 sewn onto alternate mesenteric arteries that supply the caudal small intestine starting from the 417 caecum using 4.0 nylon sutures. After it was confirmed that no bleeding was occurring in the 418 abdominal cavity, the muscle layer was closed with chromic gut suture, skin incision closed with 419 silk suture, and mice closely monitored during recovery.
420
Osmotic pump implantation and drug delivery. For Alzet osmotic pump implantation, an incision 421 was made at the nape of the mouse neck and the pump implanted immediately below the skin layer 422 and closed with silk suture for subcutaneous continuous delivery of Alda-1 (5mg/kg/day), or as a nociception, hind paw withdrawal threshold and thermal latency were assessed as a secondary or 435 referred pain-associated behavior. To assess mechanical nociception, von Frey fibers were used 436 ranging in force from 0.004 to 5.49g using the Dixon modified up and down method (52, 53).
437
Mice were placed individually in a plexi-glass chamber on an elevated mesh screen stand and 438 allowed to acclimate for a minimum of 10 minutes. Von Frey hairs were applied perpendicularly 439 to the mouse hind paw plantar surface until the hair bowed and then held for approximately 3 440 seconds. The mechanical threshold required to elicit a paw withdrawal (50% paw withdrawal 441 threshold) was determined. To assess for changes in thermal nociception, Hargreaves method was 442 used to determine latency to paw withdrawal from a focused heat light source using a commercial 443 Plantar Test Analgesia Meter (IITC Life Science) (54). Mice were placed individually in plexi-444 glass chambers on a glass platform and allowed to acclimate for a minimum of 10 minutes. The 445 heat stimulus was delivered to the plantar region of the mouse hind paw with an active intensity 446 of 30%. Reaction time was measured in .01 second increments with a cut off time of 10 seconds.
447
A minimum of 30 seconds separated each hind paw test.
448
To assess for changes in locomotor activity, mice were individually placed in an automated Opto- were previously sewn was investigated and sutures located to identify and measure the lesions in 469 situ. The ectopic lesions, eutopic uterus, and liver (control) were harvested, immediately frozen 470 in dry ice, and stored at -80C. After tissue harvesting, mice were sacrificed.
471
Mouse ectopic lesion measurement. To assess for differences in lesion size, total lesion burden 472 was first determined. To do this, the largest and smallest diameter of each lesion was multiplied 473 to give a value (most lesions have an ovoid shape) and then values from each lesion added to 474 obtain a total number, the total lesion burden (24, 60). The total lesion burden was divided by the 475 number of lesions formed to give the average lesion area for comparison between groups.
476
Tissue processing and analysis. Mouse and human tissue samples were homogenized in sucrose 477 mannitol buffer, pH 7.4 (210 mM mannitol, 70 mM sucrose, 1.0 mM EDTA, 5.0 mM MOPS) with 478 protease and phosphatase inhibitors. Briefly, tissue homogenates were centrifuged to remove 479 cellular debris and the supernatant was retained as the whole cell fraction for the analysis. Samples 480 were immediately stored at -80C until further analysis.
